GW Pharmaceuticals (GWP)

 

GWP Share PerformanceMore

52 week high0.0000 25/02/17
52 week low0.0000 25/02/17
52 week change 0.0000 (0.00%)
4 week volume0 30/01/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Exercise of Share Options, PDMR Holdings, TVR

Miscellaneous medium priority announcements

Holding(s) in Company

Notification of major interests in shares

Holding(s) in Company

Notification of major interests in shares

GW Pharmaceuticals schedules FY results

GW Pharmaceuticals will announce its fourth quarter and year-end financial results for the period ending 30 September o...

GW chief exec to present Piper Jaffray conference

GW Pharmaceuticals chief executive Justin Gover will present at the 28th annual Piper Jaffray Healthcare Conference at ...

Director Deals - GW Pharmaceuticals PLC (GWP)

Tom Lynch, Non Executive Director, sold 2,074 shares in the company on the 1st November 2016 at a price of 790.00p. Dire...

GW to trade exclusively on NASDAQ

GW Pharmaceuticals intends to cancel the admission of its ordinary shares on AIM on 5 December. The last day of trading...

Broker Forecast - Numis issues a broker note on GW Pharmaceuticals PLC

Numis today reaffirms its hold investment rating on GW Pharmaceuticals PLC (LON:GWP) and set its price target at 835p...

Equity Research (GWP)

edison investment research
GW Pharmaceuticals plc
08/06/2016
Data from two Phase III trials (with 171 and 225 patients, respectively) of Epidiolex in Lennox-Gastaut (LGS) patients are coming soon with the first trial to report out in June with the second...
edison investment research
GW Pharmaceuticals plc
25/02/2016
With four Phase III trials of Epidiolex (cannabidiol, or CBD) in various forms of pediatric epilepsy, two for Dravet syndrome and two for Lennox-Gastaut syndrome (LGS) expected to provide top-line...
edison investment research
GW Pharmaceuticals plc
25/02/2016
With four Phase III trials of Epidiolex (cannabidiol or CBD) in various forms of pediatric epilepsy, two for Dravet syndrome and two for Lennox-Gastaut syndrome (LGS) expected to provide top-line...

Latest discussion posts More

  • Re: GW AIM delisting - advice please

    Hi MischasMate, did you find a broker as I am in the same position. Thanks
    22-Dec-2016
    JC74B
  • Re: GW AIM delisting - advice please

    I don't know for sure, but AJ Bell/YouInvest have been very good for me (low commission, helpful when it came to Open Offers for GKP and SXX) and I do know that I can trade ...
    14-Dec-2016
    in4apennyin4amil1
  • GW AIM delisting - advice please

    My missus holds a load of GW & received 2 share certs from iii for her total holding (several K value in total) - well past any time to do ought about it as she was in hospital ...
    14-Dec-2016
    mishasMate

Users' HoldingsMore

Users who hold GW Pharmaceuticals also hold..
India Mid Cap A Inc GBP100%
ETFS PHYS GLD�100%
Eurpn Alp Inc Z Acc100%
ISF FronMkt Eq C Acc NV £100%
Miton UK Smaller Companies B Acc100%

Codes & Symbols

ISINGB0030544687
SymbolsGWP, LSE:GWP, GWP.L, GWP:LN, LON:GWP, XLON:GWP